Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYTH2 | Q99418 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28195816 | 0.82 | FFAR4 (0.59) | FFAR4GABRG2GABRB3GABRA3KMT2A | |
| SCHEMBL4804177 | 0.79 | FFAR4 (0.59) | FFAR4GABRG2GABRB3GABRA3RAPGEF4 | |
| SCHEMBL812692 | 0.77 | CA1 (0.63) | FFAR4GABRG2GABRB3GABRA3KMT2A | |
| SCHEMBL27960832 | 0.77 | LMNA (0.42) | FFAR4KMT2ACYTH2CA1CA2 | |
| SCHEMBL3371346 | 0.77 | TSHR (0.53) | FFAR4KMT2ACYTH2ALDH1A1 | |
| Sulfuric Acid SCHEMBL28200703 | 0.76 | RAPGEF4 (0.46) | FFAR4GABRG2GABRB3GABRA3RAPGEF4 | |
| SCHEMBL4800721 | 0.76 | FFAR4 (0.55) | FFAR4GABRG2GABRB3GABRA3RAPGEF4 | |
| SCHEMBL7258962 | 0.74 | MAPT (0.42) | KMT2ACA1CA2MMP1MMP2 | |
| SCHEMBL28314827 | 0.73 | FFAR4 (0.44) | FFAR4GABRG2GABRB3GABRA3ALDH1A1 | |
| SCHEMBL27947222 | 0.73 | MAPT (0.41) | KMT2ACA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2018-03-15 | — | — | US | disclosed |
| US-9856274-B2 | Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2016-04-14 | — | — | US | disclosed |
| US-9249162-B2 | Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | FFAR4 1202/4885GABRG2 390/4885GABRB3 311/4885 |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | FFAR4 1202/4885GABRG2 390/4885GABRB3 311/4885 |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | FFAR4 1202/4885GABRG2 390/4885GABRB3 311/4885 |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | FFAR4 1202/4885GABRG2 390/4885GABRB3 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.